Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Metastatic Cancer
Malignant Neoplasm of Lung

Interventions

DRUG: Adagrasib

Sponsor

Mirati Therapeutics Inc.